Myriad Genetics Secures Japanese Approval for Prostate Cancer Companion Diagnostic
Event summary
- Japan’s MHLW approved Myriad’s MyChoice Test for prostate cancer patients as a companion diagnostic for Lynparza.
- The test is now reimbursed under Japan’s National Health Insurance for breast, ovarian, and prostate cancers.
- Over 100,000 men are diagnosed with prostate cancer annually in Japan, with some progressing to metastatic castration-resistant prostate cancer.
- The MyChoice Test identifies homologous recombination deficiency (HRD) status and BRCA1/2 mutations to guide PARP inhibitor treatment.
The big picture
Myriad’s expansion into prostate cancer diagnostics aligns with the growing trend of precision medicine in oncology. The approval reflects Japan’s increasing focus on genomic testing to guide targeted therapies, particularly for high-burden cancers. With over 100,000 prostate cancer cases annually, this move could significantly expand Myriad’s addressable market in Japan.
What we're watching
- Market Expansion
- How quickly Myriad can drive adoption of the MyChoice Test among Japanese prostate cancer patients.
- Competitive Dynamics
- Whether this approval strengthens Myriad’s position against rivals in the precision oncology space.
- Reimbursement Impact
- The pace at which broader NHI coverage could boost Myriad’s revenue in Japan.
Related topics